Starley, B. Q., Calcagno, C. J. & Harrison, S. A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51, 1820–1832 (2010).
Tilg, H. & Moschen, A. R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6, 772–783 (2006).
Khan, A. et al. Understanding the effects of gut microbiota dysbiosis on nonalcoholic fatty liver disease and the possible probiotics role: recent updates. Int. J. Biol. Sci. 17, 818–833 (2021).
Männistö, V. et al. Serum lipopolysaccharides predict advanced liver disease in the general population. JHEP Rep. 1, 345–352 (2019).
Miura, K. et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1β in mice. Gastroenterology 139, 323-334.e7 (2010).
Miura, K. et al. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology 57, 577–589 (2013).
Miura, K. et al. Toll-like receptor 4 on macrophage promotes the development of steatohepatitis-related hepatocellular carcinoma in mice. J. Biol. Chem. 291, 11504–11517 (2016).
Okubo, H. et al. Lactobacillus casei strain shirota protects against nonalcoholic steatohepatitis development in a rodent model. Am. J. Physiol. Gastrointest. Liver Physiol. 305, 911–918 (2013).
Park, E.-J. et al. Beneficial effects of lactobacillus plantarum strains on non-alcoholic fatty liver disease in high fat/high fructose diet-fed rats. Nutrients 12, 542 (2020).
Febbraio, M. A. et al. Preclinical models for studying NASH-Driven HCC: how useful are they?. Cell Metab. 29, 18–26 (2019).
Lange, N. F., Radu, P. & Dufour, J. F. Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention. J. Hepatol. 75, 1217–1227 (2021).
Horie, Y. et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest. 113, 1774–1783 (2004).
Stiles, B. et al. Live-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity. Proc. Natl. Acad. Sci. U. S. A. 101, 2082–2087 (2004).
Galicia, V. A. et al. Expansion of hepatic tumor progenitor cells in pten-null mice requires liver injury and is reversed by loss of AKT2. Gastroenterology 139, 2170–2182 (2010).
Hu, T. H. et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 97, 1929–1940 (2003).
Nomoto, K., Tsuneyama, K., Takahashi, H., Murai, Y. & Takano, Y. Cytoplasmic fine granular expression of 8-hydroxydeoxyguanosine reflects early mitochondrial oxidative DNA damage in nonalcoholic fatty liver disease. Appl. Immunohistochem. Mol. Morphol. AIMM 16, 71–75 (2008).
Miura, K. et al. Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet. Cancer Sci. 110, 771–783 (2019).
Kim, B. et al. Protective effects of Lactobacillus rhamnosus GG against dyslipidemia in high-fat diet-induced obese mice. Biochem. Biophys. Res. Commun. 473, 530–536 (2016).
Zhao, Z. et al. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation. Appl. Microbiol. Biotechnol. 104, 5273–5282 (2020).
Bubnov, R. V. et al. Comparative study of probiotic effects of Lactobacillus and Bifidobacteria strains on cholesterol levels, liver morphology and the gut microbiota in obese mice. EPMA J. 8, 357–376 (2017).
Dang, X., Xu, M., Liu, D., Zhou, D. & Yang, W. Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: a systematic review and meta-analysis. PLoS ONE 15, 1–16 (2020).
Velayudham, A. et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 49, 989–997 (2009).
Esposito, E. et al. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J. Nutr. 139, 905–911 (2009).
Ishioka, M., Miura, K., Minami, S., Shimura, Y. & Ohnishi, H. Altered gut microbiota composition and immune response in experimental steatohepatitis mouse models. Dig. Dis. Sci. 62, 396–406 (2017).
Day, C. P. & James, O. F. Steatohepatitis: a tale of two ‘hits’?. Gastroenterology 114, 842–845 (1998).
Yamaguchi, K. et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45, 1366–1374 (2007).
Gluchowski, N. L. et al. Hepatocyte deletion of triglyceride-synthesis enzyme acyl CoA: diacylglycerol acyltransferase 2 reduces steatosis without increasing inflammation or fibrosis in mice. Hepatology 70, 1972–1985 (2019).
Puri, P. et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46, 1081–1090 (2007).
Caballero, F. et al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J. Hepatol. 50, 789–796 (2009).
Kumar, M. et al. Effect of probiotic fermented milk and chlorophyllin on gene expressions and genotoxicity during AFB 1-induced hepatocellular carcinoma. Gene 490, 54–59 (2011).
Zhang, H. L. et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J. Hepatol. 57, 803–812 (2012).
Li, J. et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc. Natl. Acad. Sci. U. S. A. 113, E1306–E1315 (2016).
Shimizu, Y. et al. Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model. J. Gastroenterol. Hepatol. 36, 800–810 (2021).
Kalhan, S. C. et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 60, 404–413 (2011).
Luz Martínez-Chantar, M. et al. Importane of a deficiency in S-adenosyl-L-methionine sysnthesis in the pathogenesis of liver injury. Am. J. Clin. Nutr. 76, 1177S-1182S (2002).
Wong, V.W.-S., Adams, L. A., de Lédinghen, V., Wong, G.L.-H. & Sookoian, S. Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. Nat. Rev. Gastroenterol. Hepatol. 15, 461–478 (2018).
Ye, Q. et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 5, 739–752 (2020).
Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005).
Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675 (2012).
Kanda, Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48, 452–458 (2013).